ATRC · AtriCure, Inc.

AtriCure's Q1 2026 results demonstrate accelerating growth and a pivotal shift to profitability, with worldwide revenue reaching $141.2 million, up 14.3% year-over-year, and U.S. revenue surging 14.9% to $116.2 million. Key drivers included strong performances from cryoSPHERE MAX probe in pain management ($22.4 million, up from $17.3 million), AtriClip devices in appendage management ($48.4 million, up from $42.1 million), and EnCompass clamp in open ablation. International revenue grew 11.5% to $25.0 million. Gross margin expanded 246 basis points to 77.4%, reflecting favorable product and geographic mix. Operating income flipped to $0.5 million from a $6.0 million loss, while adjusted EBITDA more than doubled to $17.1 million, underscoring operational leverage amid controlled expense growth in R&D and SG&A. CEO Michael Carrel highlighted the durability of the growth model, driven by disciplined execution and innovative product adoption in Afib, LAA management, and pain therapies. Full-year 2026 guidance signals confidence with revenue projected at $600-610 million and adjusted EBITDA at $80-82 million, alongside positive cash flow. Balance sheet remains solid with $146.2 million in cash, reduced current liabilities, and manageable $61 million long-term debt. This corrected 8-K/A filing reinforces AtriCure's trajectory toward sustained profitability and shareholder value creation.